StockNews.AI
VNDA
StockNews.AI
84 days

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

1. VNDA to present at ASCP Annual Meeting in May 2025. 2. Presentation includes pharmacokinetic studies of Milsaperidone and Iloperidone. 3. Bysanti™, a new atypical antipsychotic, may be approved by 2026. 4. Pending patent applications could extend market exclusivity into the 2040s. 5. VNDA focuses on high unmet medical needs in biopharmaceuticals.

4m saved
Insight
Article

FAQ

Why Bullish?

VNDA’s participation in a key conference indicates strong pipeline potential, similar to past events that sparked investor interest.

How important is it?

The announcement of Bysanti™ and upcoming presentations are crucial for VNDA’s growth narrative.

Why Long Term?

Approval of Bysanti™ by 2026 can significantly enhance VNDA's market position and revenues for years.

Related Companies

ILPNMILSPFE
, /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, to be held in Scottsdale, Arizona, from May 27 through May 30, 2025. The following will be presented: May 27, 2025 Presentation Title: "Pharmacokinetic Results of Single-Dose and Multiple-Dose Bioequivalence Studies of Milsaperidone and Iloperidone Immediate-Release Oral Tablets"Poster Presentation Session: IIPoster Number: T19Presenter: Sean R. Chadwick, PhD, Clinical Development About Bysanti™ Bysanti™ is a new chemical entity that belongs in the class of atypical antipsychotic drugs. If approved, Bysanti™ could be available for sale in the US in 2026. Bysanti™ is believed to achieve its therapeutic effect by interacting with a host of neurotransmitter receptors in the brain, including the alpha-adrenergic receptor, serotonin receptors and dopamine receptors. Exclusivity, including pending patent applications, could extend into the 2040s. About Vanda Pharmaceuticals Inc. Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma. Corporate Contact: Kevin MoranSenior Vice President, Chief Financial Officer and Treasurer Vanda Pharmaceuticals Inc.202-734-3400[email protected] Jim Golden/Jack Keleher/Dan MooreCollected Strategies[email protected]  SOURCE Vanda Pharmaceuticals Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News